This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. Check our privacy policy here
News and Events
La compostelana SunRock y el Instituto de Oncología del Vall d’Hebron reciben 1,8 millones de euros de la Agencia Estatal de Investigación para el desarrollo de nuevos anticuerpos en el tratamiento del cáncer de ovario
El consorcio integrado por SunRock Biopharma, con sede en el Biopolo Sionlla, y por VHIO lidera el proyecto OVERCAD,…
SunRock Biopharma will be giving an oral presentation on its anti-CCR9 antibody for IBD in ECCO25, Berlin.
SunRock’s communication has been selected for oral presentation at the 20th Congress of ECCO, February 19-22, 2025, Berlin, Germany. DOP065 SRB1:…
Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today secured an…
Events
SunRock Biopharma, S.L will be attending the BIOEurope Spring 2025 in Milan from 17-19 March
We are a biotech company with a pipeline of therapeutic antibodies for the treatment of cancer and immune-mediated inflammatory diseases, including…
SunRock Biopharma will be attending the 20th Congress of ECCO European Crohn’ and Colitis Organisation in Berlin from 19-22 February
We are a hashtag#biotech company with a pipeline of therapeutic hashtag#antibodies for the treatment of hashtag#inflammatory hashtag#bowel hashtag#disease. Are you attending…
Projects
